Cargando…

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis

Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and organs. In most patients with systemic mastocytosis, the neoplastic cells carry activating mutations in KIT. Progress in mastocytosis research has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arock, Michel, Wedeh, Ghaith, Hoermann, Gregor, Bibi, Siham, Akin, Cem, Peter, Barbara, Gleixner, Karoline V., Hartmann, Karin, Butterfield, Joseph H., Metcalfe, Dean D., Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278969/ https://www.ncbi.nlm.nih.gov/pubmed/29976735 http://dx.doi.org/10.3324/haematol.2018.195867

Ejemplares similares

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine
por: Valent, Peter, et al.
Publicado: (2020)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Clinical presentation and markers of cutaneous versus systemic mastocytosis: the mastocytosis center at brigham and women's hospital in Boston
por: Kanamori, Kelly Yoshimi, et al.
Publicado: (2015)

Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy
por: Niedoszytko, Marek, et al.
Publicado: (2021)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis
por: Brockow, Knut, et al.
Publicado: (2021)

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023)

Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022
por: Valent, Peter, et al.
Publicado: (2022)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
por: Kaakati, Rayan, et al.
Publicado: (2021)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

PD-L1 Expression in Mastocytosis
por: Williams, Margaret, et al.
Publicado: (2019)

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal()
por: Valent, Peter, et al.
Publicado: (2017)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients
por: Boehm, Thomas, et al.
Publicado: (2019)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
por: Valent, Peter, et al.
Publicado: (2022)

A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders
por: Romantowski, Jan, et al.
Publicado: (2021)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021
por: Lange, Magdalena, et al.
Publicado: (2021)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Challenges in applying diagnostic criteria for systemic mastocytosis
por: Boggs, Nathan A., et al.
Publicado: (2023)

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
por: Kluin-Nelemans, Hanneke C., et al.
Publicado: (2021)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis
por: Hermine, Olivier, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_d7ls1sc79m24781ps0b54g400q